Effectiveness of minocycline‐based triple therapy for eradication of <i>Helicobacter pylori</i> infection

Murakami, Kazunari; Sato, Ryugo; Watanabe, Koichiro; Nasu, Masaru; Fujioka, Toshio; Kodama, Masaaki; Abe, T; Sato, Shunzo; Arita, Tsuyoshi

doi:10.1111/j.1440-1746.2006.04183.x

Cited by 33 publications

(57 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies reporting duplicate data were excluded. After careful evaluation, 36 studies (including 3466 patients) were found to perform antibiotic susceptibility determinations and were included in the systematic review. Of these 36 articles, 24 reported cure rates according to antibiotic resistances/susceptibilities, including 37 arms of treatment.…”

Section: Resultsmentioning

confidence: 99%

Systematic review: Would susceptibility‐guided treatment achieve acceptable cure rates for second‐line Helicobacter pylori therapy as currently practiced?

et al. 2019

View full text Add to dashboard Cite

Background Susceptibility‐guided treatment has been proposed as a way to improve Helicobacter pylori eradication rates. Evidence on its efficacy for rescue therapy is very scarce. The aim of this study was to indirectly assess the applicability and effectiveness of susceptibility‐guided treatment by evaluating (a) the rate of acceptance of endoscopy, (b) its success in detecting resistances, and (c) infection cure rates in patients harboring strains found to be susceptible to the antibiotics administered in clinical trials in which the efficacy of second‐line treatments was reported. Methods A systematic review of studies evaluating second‐line H pylori treatment was carried out in multiple databases. Studies reporting antibiotic susceptibility evaluation and/or cure rates in patients harboring sensitive and resistant strains were selected. Data were extracted in duplicate. Results The systematic review identified 36 eligible studies. Acceptance was evaluated in only one study of 60 patients, of whom only 38 agreed to endoscopy. Among the 2890 patients who received endoscopy and culture, resistances were finally determined in 86.5%. Cure rate was 72.5% in the 113 patients harboring a clarithromycin‐susceptible strain after previous clarithromycin treatment, 93.5% in the 765 patients harboring a metronidazole‐susceptible strain, and 83.8% in the 192 patients harboring a levofloxacin‐susceptible strain. No studies with repeated administration of levofloxacin or metronidazole were found. Conclusion Even if the culture shows a clarithromycin‐sensitive strain, repeating clarithromycin after a first failure should be discouraged. Susceptibility‐guided treatment alone did not achieve adequate cure rates for rescue therapies. Additional measures are needed to design rescue treatments that consistently achieve excellent cure rates.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic review: Would susceptibility‐guided treatment achieve acceptable cure rates for second‐line Helicobacter pylori therapy as currently practiced?

et al. 2019

View full text Add to dashboard Cite

show abstract

“…shows a disappointing e ectiveness (38.5%) [13]. However, the case of a multi-resistant H. pylori strain successfully treated with minocycline/amoxicillin/bismuth has been described [14].…”

Section: Discussionmentioning

confidence: 99%

Quadruple Rescue erapy aer First and Second Line Failure for Helicobacter pylori Treatment: Comparison between Two Tetracycline-Based Regimens

Ierardi

Giangaspero

Losurdo

et al. 2014

JGLD

View full text Add to dashboard Cite

Background & Aims: Antibiotic resistance is the main reason for failure of Helicobacter pylori (H. pylori) treatment. Currently, guidelines recommend a treatment guided by antimicrobial susceptibility testing after two failures. However, microbial culture is not feasible everywhere, and the limited number of effective antibiotics against the bacterium narrows the options; thus a rescue therapy combining antibiotics with a low resistance may be fitting.Methods: Patients who have failed a first-line treatment (either prolonged triple or sequential regimens) and, successively, a levofloxacin-based triple therapy were considered for the study. Subjects underwent urea breath test (UBT), stool antigen test (ST) and endoscopy/histology to confirm the diagnosis. Cytopenia and impaired liver and kidney function were exclusion criteria. Fifty-four subjects were randomized 1:1 to two regimens: RMB Rabeprazole/Rifabutin/Minocycline/Bismuth sub-citrate or MTB Rabeprazole/Tinidazole/ Minocycline/Bismuth sub-citrate both for 10 days. The results were checked 6 weeks after the end of therapy with ST/UBT plus endoscopy when indicated.Results: RMB eradicated the bacterium in 21 patients. Two subjects dropped out. The eradication rate was 77.7% (CI 62.0-93.4%) at intention-to-treat and 84.0% (CI 69.6-98.4%) at per-protocol analysis. MTB was successful in 14 patients (51.9%, CI 33.1-70.7%). No patient withdrew from the treatment for adverse events. Drug-related side effects were reported only in 3 subjects, but in all cases the treatment was carried on.Conclusions: The association minocycline/rifabutin seems to have a synergic effect and a good therapeutic outcome in patients who have failed at least two previous regimens, although a trial on a large population is needed.

show abstract

“…Two studies on the use of faropenem in antimicrobial therapy for H. pylori have been published [22,23]. Togawa et al.…”

Section: Discussionmentioning

confidence: 99%

“…Previous data demonstrated that faropenem has a very low minimum inhibitory concentration (MIC) against H. pylori [21]. Two eradication studies with faropenem have been performed, but they found widely differing eradication rates of 91.3 and 9.5%[22,23]. We report the MIC of faropenem against 78 clinical H. pylori isolates from Japanese.…”

mentioning

confidence: 98%

Efficacy and Safety of Faropenem in Eradication Therapy of Helicobacter pylori

Ogura¹,

Mitsuno²,

Maeda³

et al. 2007

Helicobacter

View full text Add to dashboard Cite

show abstract

Effectiveness of minocycline‐based triple therapy for eradication of Helicobacter pylori infection

Cited by 33 publications

References 18 publications

Systematic review: Would susceptibility‐guided treatment achieve acceptable cure rates for second‐line Helicobacter pylori therapy as currently practiced?

Systematic review: Would susceptibility‐guided treatment achieve acceptable cure rates for second‐line Helicobacter pylori therapy as currently practiced?

Quadruple Rescue erapy aer First and Second Line Failure for Helicobacter pylori Treatment: Comparison between Two Tetracycline-Based Regimens

Efficacy and Safety of Faropenem in Eradication Therapy of Helicobacter pylori

Contact Info

Product

Resources

About